期刊文献+

骨保护素体外抑制小鼠单核巨噬细胞成熟分化的实验研究 被引量:6

Study on osteoprotegerin in inhibitation of mouse osteoclast precursor cell differentiation
下载PDF
导出
摘要 目的研究骨保护素(Osteoprotegerin,OPG)抑制核因子NF-κB受体活化因子配体(Receptoractivator of nuclear kappa B ligand,RANKL)诱导小鼠单核细胞RAW264.7成熟分化而导致的溶骨效应。方法 50 ng/mL RANKL诱导RAW264.7细胞1 d后,加入100 ng/mL OPG(实验组,即OPG+RANKL组)或不加入OPG(对照组,即RANKL组)分别培养7 d和9 d,经细胞形态学观察其变化,抗酒石酸酸性磷酸酶(Tartrate resistant acid phosphatase,TRAP)染色法观察TRAP阳性多核细胞,扫描电镜下观察在骨片上的破骨细胞所致的骨吸收陷窝形成情况。结果对照组培养7 d时,在倒置相差显微镜、透射电镜、光镜下可见细胞形状为椭圆形或不规则形,胞体明显较RAW264.7细胞增大,胞核多为6~10个,扫描电镜下还可见大量伪足形成,而实验组培养7 d后,细胞形状多为圆形,且扫描电镜下未见明显伪足形成;对照组9 d时可见大量TRAP染色阳性的多核巨细胞(含3个或3个以上的细胞核),而实验组中TRAP染色阳性的多核破骨细胞偶见多核巨细胞,培养9 d时很难找到多核巨细胞;仅用RANKL诱导RAW264.7细胞分化7 d时,对照组中破骨细胞表面可见大量伪足伸出,并形成明显的骨吸收陷窝,实验组中破骨细胞见少许伪足突出,不能看到明显的骨陷窝形成。结论单用50 ng/mL RANKL体外连续诱导RAW264.7细胞7 d时,可以促进成熟的破骨细胞显著分化。100 ng/mL OPG培养9 d能有效地抑制破骨细胞的分化,减少破骨细胞的骨吸收效应。 Objective To observe whether OPG is effective in inhibiting the effect that RANKL induce RAW264.7 ceils to differentiation to mature osteoclast. Methods RAW264. 7 cells were solely treated with 50 ng/ml RANKL for 1 day, which then were divided into two groups: the one is an OPG group involving 100 ng/ml OPG and 50 ng/ml RANKL, the other is a control group only containing 50 ng/ml RANKL. After the period between 7 and 9 d, cells morphological changes can be investigated by Inverted Phase Control Microscope (IPCM) , Transmission Electron Microscope (TEM) , Scanning Electron Microscope (SEM) and Light Microscope respectively; Furthermore, Staining TRAP-positive multinucleated cells can be detected by IPCM;The resorption pits of bone slices were indicated through SEM. Results It is very clear that the sharp of RAW264.7 cells became oval or irregular, and their bodies go bigger significantly including 6 up to 10 nucleus in control group by means of IPCM, TEM and Light Microscope. Interestingly, we also have found that there were considerable pseudopodia-like protrusions attaching to the surface of these cells by Scanning Electron Microscopy in the control group. By contrast, the research result is polar in OPG group.The outcome of experiment has further demonstrated that RAW264.7 ceils treated by RANKL in consecutive 7 days performed more highly dramatic numbers of staining TRAP-positive multinucleated osteoelasts (more than 3 nucleus) in control group than corresponding OPG group; Finally, in terms of the number of bone resorption formation, control group has overwhelmingly outweighed than the OPG group. Conclusion RAW264. 7 cells could be successfully induced differentiation to mature osteoclasts on the condition of single 50ng/ml RANKL, especially in excess of 7 d. The interference of 100 ng/ml OPG in 9 days could be extremely beneficial to inhibit the process in osteoelasts differentiation and reduce the effect on bone resorption in an effeetive approach.
出处 《中国骨质疏松杂志》 CAS CSCD 北大核心 2013年第3期247-250,211,共5页 Chinese Journal of Osteoporosis
基金 贵州省科技厅遵义医学院遵义市科技局联合基金(黔科合J字LKZ[2012]07号)
关键词 破骨细胞 骨质疏松 RAW264.7细胞 RANKL OPG Osteoclasts Osteoporosis RAW264.7 ceils RANKL OPG
  • 相关文献

参考文献13

  • 1黄传兵.骨质疏松症的危险因素及防治[J].中国初级卫生保健,2003,17(3):76-76. 被引量:6
  • 2Deal C. Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol, 2009,5 ( 3 ) : 174.
  • 3Faccio R,Takeshita S,Zallone A,et al. c-Fms and αvβ3 integrin collaborate during osteoclnst differentiation. J Clin Invest,2003, 111:749-758.
  • 4Wright HI,, McCarthy HS, Middleton J,et al. RANK/ RANKL and osteoprotegerin in bone biology and disease. Curt Rev Musculoskelet Med .2009.2( 1 ) :56-64.
  • 5Battaglino R,Kim D, Fu J, et al. c-myc is required for osteoclast differentiation. J Bone Miner Res,2002,17 (5) :763-773.
  • 6Sasaki N, Kusano E. Bone and bone related biochemical examinations. Bone and collagen related metabolites. Measurement and clinical role of OPG. Clin Calcium, 2006, 16(6):956-962.
  • 7Parfitt AM. Targeted and nontargeted bone remodeling: relationship to basic muhieellular unit origination and progression. Bone ,2002,30(1 ) :5-7.
  • 8Simonet WS, Lacey DL, Dunstan C, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell, 1997,89 ( 2 ) : 309-319.
  • 9Gori F, Hofbauer LC, Dunstan CR, et al. The expression of osteoprotegerin and RANK ligand:and the support of osteociast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology,2000,141 ( 12 ) :4768-4776.
  • 10Tsuda E, Goto M, Mochizuki SI, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. J Biochemical and Biophysical Research Communications, 1997,234 ( 1 ) : 137-142.

二级参考文献32

  • 1Blair HC,Robinson LJ,Zaidi M.Osteoclast signalling pathways.Biochem Biophy Res Commun,2005,328:728-738.
  • 2Faccio R,Takeshita S,Zallone A,et al.c-Fms and ανβ3 integrin collaborate during osteoclnst differentiation.J Clin Invest,2003,111:749-758.
  • 3Looney RJ,Schwarz EM,Boyd A,et al.Periprosthetic osteolysis:an immunologist's update.Curr Opin Pharmacol,2006,18(1):80-87.
  • 4Lynch CC,Hikosaka A,Acuff HB,et al.MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL.Cancer Cell,2005,7(5):485-496.
  • 5Kostenuik PJ.Osteoprotegerin and RANKL regulate bone resorption,density,geometry and strength.Curr Opin Pharmacol,2005,5(6):618-625.
  • 6Armstrong AP,Tometsko ME,Glaccum M,et al.A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclas cytoskeletal organization and resorptive function.J Biol Chem,2002,277:44:347-356.
  • 7Weda T,Nakashima T,Oliveira-dos-Santos AJ,et al.The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis.Nat Med,2005,11(4):394-399.
  • 8Matzke M,Matzke AJ,Kooter JM.RNA:guiding gene silencing.Science,2001,293(5532):1080-1083.
  • 9Hagmtmn C,Blank JI.The ups and downs of MEK kinase interactions.Cell Sis,2001,13:863-875.
  • 10Kakis JM,Avruch J.Mannalian mitogen-activated protein kinase signal transduction pathways activated by stress an inflammation.Physiol Rev,2001,81(2):801-809.

共引文献13

同被引文献72

  • 1赵梅,韩伟.Notch信号传导通路相关疾病的研究进展[J].生物化学与生物物理进展,2006,33(12):1154-1160. 被引量:12
  • 2Kanis JA. Assessment of osteoporosis at the primary health care level[R].Geneva:WHO Scientific Group Technical Report,2007.
  • 3Strom O, Borgstrom F, Kanis JA, et al. Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the international osteoporosis foundation(IOF)and the european federation of pharmaceutical industry associations(EFPIA)[J]. Arch Osteoporos,2011, 6(1-2): 59-155.
  • 4Harvey N, Dennison E, Cooper C. Osteoporosis: impact on health and economics[J]. Nat Rev Rheumatol,2010,6(2): 99-105.
  • 5Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future[J]. Lancet,2011,377: 1276-1287.
  • 6Mundy GR, Elefteriou F. Boning up on ephrin signaling[J].Cell,2006,126(3): 441-443.
  • 7Khosla S. Minireview: the OPG/RANKL/RANK system[J]. Endocrinology,2001,142(12): 5050-5055.
  • 8Tokuyama N, Tanaka S.Cytokines in bone diseases:genetic disorders of RANKL-RANK-OPG system[J]. Clin Calcium,2010,20(10): 1532-1538.
  • 9Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density[J]. Cell,1997,89(2): 309-319.
  • 10Tsuda E, Goto M, Mochizuki S, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis[J]. Biochem Biophys Res Commun,1997,234(1): 137-142.

引证文献6

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部